Drug Profile
SC 113
Latest Information Update: 04 Jul 2000
Price :
$50
*
At a glance
- Originator Scotia Holdings [CEASED]
- Class
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors; Prostaglandin synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia; Erectile dysfunction
Most Recent Events
- 04 Jul 2000 Discontinued-Preclinical for Benign prostatic hyperplasia in United Kingdom (Unknown route)
- 04 Jul 2000 Discontinued-Preclinical for Erectile dysfunction in United Kingdom (Unknown route)
- 08 Sep 1998 No-Development-Reported for Benign prostatic hyperplasia in United Kingdom (Unknown route)